Clinical Updates in Rheumatoid Arthritis
Evolving Treatment Algorithms and Expert Perspectives on Biosimilars
Clinical Updates in Rheumatoid Arthritis
American College of Rheumatology Annual Meeting Abstract Archives
2016 Annual Meeting held in Washington, DC, November 11-16, 2016.
American College of Rheumatology Position Statement on Biosimilars
American College of Rheumatology. Released April 2016.
Annual European Congress of Rheumatology 2016 Abstracts
Hosted by the European League Against Rheumatism (EULAR) in London, England, June 14-17, 2016.
Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis
Choy E. Rheumatology (Oxford). 2012;51(suppl 5):v3-v11.
Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I.
Helmick CG, et al. Arthritis Rheum. 2008;58(1):15-25.
Safety and efficacy of biological disease-modifying antirheumatic drugs in older rheumatoid arthritis patients: staying the distance.
Ishchenko A, Lories RJ. Drugs Aging. 2016;33(6):387-398.
Cardiovascular risk and the use of biologic agents in rheumatoid arthritis.
Lim DT, et al. Curr Rheumatol Rep. 2014;16(11):459. 2012;130(2):332-342.e10.
Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy.
Nishimoto N, et al. Mod Rheumatol. 2009;19(1):12-19.
Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial.
Gabay C, et al. Lancet. 2013;4:381(9877):1541-1550.
Preclinical lung disease in early rheumatoid arthritis.
Robles-Perez A, et al. Chron Respir Dis. 2016;13(1):75-81.
The pathogenesis of rheumatoid arthritis: new insights from old clinical data?
Smolen JS, et al. Nat Rev Rheumatol. 2012;8(4):235-243
Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study.
Tanaka Y, et al. Ann Rheum Dis. 2015;74(2):389-395.
Mortality in rheumatoid arthritis. Increased in the early course of disease, in ischaemic heart disease and in pulmonary fibrosis
Young A, et al. Rheumatology (Oxford). 2007;46(2):350-357
Clinical Practice Guidelines
2015 American College of Rheumatology Guidelines for the Treatment of Rheumatoid Arthritis.
Singh JA, et al. Arthritis Rheumatol. 2016;68(1):1-26.
EULAR Recommendations for the Management of Rheumatoid Arthritis With Synthetic and Biological Disease-Modifying Antirheumatic Drugs: 2013 Update
Smolen JS, et al. Ann Rheum Dis. 2014;73(3):492-509.
Treating Rheumatoid Arthritis to Target: 2014 Update of the Recommendations of an International Task Force
Smolen JS, et al. Ann Rheum Dis. 2016;75(1):3-15
Patient Resources
American College of Rheumatology
The American College of Rheumatology provides information for patients and caregivers that covers a breadth of topics, including the effects of rheumatoid arthritis (RA), importance of early treatment, access to biologic medications, patient advocacy, and more
Arthritis Foundation
The Arthritis Foundation provides self-care tools and resources covering treatment options, pain management, diet and exercise, and common comorbidities associated with RA.
NIAMS Handout on Health: Rheumatoid Arthritis
This National Institute of Arthritis and Musculoskeletal and Skin Diseases publication is a resource for patients and their families that describes how RA develops, how it is diagnosed, and how it is treated. It also highlights current research efforts and addresses what people can do to help self-manage their disease.
Rheumatoid Arthritis Support Network
The Rheumatoid Arthritis Support Network is dedicated to providing up-to-date information and resources for patients with RA.
Clinical Assessment Tools
American College of Rheumatology Disease Activity and Functional Status Assessment Online Calculators
The American College of Rheumatology has endorsed several RA disease activity measures, formatted as online calculators, to facilitate clinical decision-making.
Clinical Disease Activity Index (CDAI)
The CDAI for RA is a validated instrument that has providers survey 28 joints, the results of which are integrated with the patient’s and clinician’s global health assessment (Aletaha D, et al. Arthritis Res Ther. 2005;7(4):R796-R806).
Disease Activity Score (DAS28)
The DAS28 is a measure of RA disease activity that combines an assessment of 28 joints, results from laboratory testing (DAS28-ESR or DAS28-CRP), and a visual analog scale (Van Der Heijde DMFM, et al. J Rheumatol. 1993;20(3):579-581; Van Gestel AM, et al. Arthritis Rheum. 1998;41(10):1845-1850).
Routine Assessment of Patient Index Data 3 (RAPID3)
RAPID3 is a pooled index of the 3 patient-reported measures from the ACR Core Data Set for RA: function, pain, and patient global estimate of status (Pincus T, et al. Rheum Dis Clin North Am. 2009;35(4):773-778).
Simplified Disease Activity Index (SDAI)
Similar to the CDAI, the SDAI for RA has providers survey 28 joints, incorporates the patient’s and clinician’s global health assessment, and includes the circulating level of C-reactive protein (Smolen JS, et al. Rheumatol. 2003;42(2):244-257).
